The five-year follow-up data from CheckMate 649, presented at the 2025 ASCO Gastrointestinal Cancers Symposium, confirms the long-term survival benefits of nivolumab plus chemotherapy in advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma. This combination continues to surpass chemotherapy alone, delivering improved overall survival, durable responses, and a consistent safety profile across patient subgroups, reinforcing its role as a standard first-line treatment.
This study marks the longest follow-up of an anti–PD-1 plus chemotherapy regimen in this setting.
Thanks to the dedicated researchers and clinicians whose work continues to shape the future of treatment for patients worldwide.
Published in Journal of Clinical Oncology : https://lnkd.in/eFwqtCXU.
